Objective: Gene expression patterns differ in the two types of skeletal muscle fiber. The Wnt signaling pathway, which includes low-density lipoprotein receptor-related protein 6 (LRP6), has been associated with cell differentiation and glucose metabolism in skeletal muscles. We examined the relationships between muscle fiber types and LRP6 expression. Methods: Adenosine triphosphatase was assayed histochemically, and the levels of expression of LRP6 and myosin were analyzed immunohistochemically, in frozen sections of muscle fiber obtained from 16 muscle biopsy samples. The expression pattern of LRP6 in C2C12 cells was assayed by immunocytochemistry. Results: LRP6 was expressed only in type II fibers. Type IIc fibers showed variations in LRP6 expression. Expression of LRP6 was observed at the stage of myoblast differentiation. Conclusion: Antibody to LRP6 may be useful for identifying type II skeletal muscle fibers. LRP6 may influence glucose metabolism in type II fibers of human skeletal muscles.

Keywords:
Low-density lipoprotein receptor-related protein 6, Muscle fiber type, Skeletal muscle, Wnt signaling
1.
Schiaffino S, Reggiani C: Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996;76:371-423.
2.
Buller AJ, Eccles JC, Eccles RM: Interactions between motoneurones and muscles in respect of the characteristic speeds of their responses. J Physiol 1960;150:417-439.
3.
Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, Bassel-Duby R, Williams RS: A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998;12:2499-2509.
4.
Termin A, Staron RS, Pette D: Myosin heavy chain isoforms in histochemically defined fiber types of rat muscle. Histochemistry 1989;92:453-457.
5.
Horton MJ, Brandon CA, Morris TJ, Braun TW, Yaw KM, Sciote JJ: Abundant expression of myosin heavy-chain IIb RNA in a subset of human masseter muscle fibres. Arch Oral Biol 2001;46:1039-1050.
6.
Weatherbee SD, Anderson KV, Niswander LA: LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006;133:4993-5000.
7.
Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S: Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259:427-435.
8.
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638-642.
9.
Carthy JM, Garmaroudi FS, Luo Z, McManus BM: Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner. PLoS One 2011;6:e19809.
10.
George SJ: Regulation of myofibroblast differentiation by convergence of the Wnt and TGF-beta1/Smad signaling pathways. J Mol Cell Cardiol 2009;46:610-611.
11.
Anakwe K: Wnt signalling regulates myogenic differentiation in the developing avian wing. Development 2003;130:3503-3514.
12.
Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC: An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000;407:535-538.
13.
Singh R, De Aguiar RB, Naik S, Mani S, Ostadsharif K, Wencker D, Sotoudeh M, Malekzadeh R, Sherwin RS, Mani A: LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans. Cell Metab 2013;17:197-209.
14.
Brooke MH, Kaiser KK: Three ‘myosin adenosine triphosphatase' systems: the nature of their pH lability and sulfhydryl dependence. J Histochem Cytochem 1970;18:670-672.
15.
Bárány M: ATPase activity of myosin correlated with speed of muscle shortening. J Gen Physiol 1967;50(suppl):197-218.
16.
Neunhauserer D, Zebedin M, Obermoser M, Moser G, Tauber M, Niebauer J, Resch H, Galler S: Human skeletal muscle: transition between fast and slow fibre types. Pflugers Arch 2011;461:537-543.
17.
Simon-Chazottes D, Tutois S, Kuehn M, Evans M, Bourgade F, Cook S, Davisson MT, Guenet JL: Mutations in the gene encoding the low-density lipoprotein receptor LRP4 cause abnormal limb development in the mouse. Genomics 2006;87:673-677.
18.
Han XH, Jin YR, Seto M, Yoon JK: A WNT/beta-catenin signaling activator, R-spondin, plays positive regulatory roles during skeletal myogenesis. J Biol Chem 2011;286:10649-10659.
19.
Tanaka S, Terada K, Nohno T: Canonical Wnt signaling is involved in switching from cell proliferation to myogenic differentiation of mouse myoblast cells. J Mol Signal 2011;6:12.
20.
Liu W, Singh R, Choi CS, Lee HY, Keramati AR, Samuel VT, Lifton RP, Shulman GI, Mani A: Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure. J Biol Chem 2012;287:7213-7223.
21.
Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP: LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278-1282.
22.
Henriksen EJ, Bourey RE, Rodnick KJ, Koranyi L, Permutt MA, Holloszy JO: Glucose transporter protein content and glucose transport capacity in rat skeletal muscles. Am J Physiol 1990;259:E593-E598.
23.
Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, Chang W, Thompson TC: Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res 2013;73:1900-1911.
24.
Oh YS, Kim HJ, Ryu SJ, Cho KA, Park YS, Park H, Kim M, Kim CK, Park SC: Exercise type and muscle fiber specific induction of caveolin-1 expression for insulin sensitivity of skeletal muscle. Exp Mol Med 2007;39:395-401.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.